Abstract
Background Obesity along with clustering of cardiovascular risk factors is a promoter for coronary artery disease. On the other hand, a high BMI appears to exert a protective effect with respect to outcomes after a coronary artery event, termed the obesity paradox.
Methods The Swedish Coronary and Angiography and Angioplasty registry (SCAAR) collects information on all patients who undergo percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) in Sweden along with demographic- and procedure-related data. We studied the predictability of four categories of BMI for 1-year all-cause mortality in people with STEMI undergoing PCI.
Results Among 25,384 patients, mean (SD) age 67.7 (12.1) years and 71.1% male, who underwent PCI for STEMI a total of 5,529 (21.8%) died within one year. Using normal-weight (BMI 18.5-24.9 kg/m2) as a reference, subjects with obesity (BMI ≥30 kg/m2) had a low 1-year all-cause mortality risk in unadjusted analysis, HR 0.59 (95% CI 0.53– 0.67). However, after adjustment for age, sex and other covariates the difference became non-significant, HR 0.88 (95% CI: 0.75-1.02). Patients with overweight (BMI 25.0-29.9 kg/m2) had the lowest 1-year mortality risk in analysis adjusted for age, sex and other covariates, HR 0.87 (95% CI 0.79-0.95), whereas those with underweight (BMI <18.5 kg/m2) had the highest mortality in both unadjusted HR 2.22 (95% CI 1.69–2.92) and adjusted analysis, HR 1.72 (95% CI: 1.31-2.26).
Conclusion The protective effect of obesity with respect to 1-year mortality after coronary intervention became non-significant after adjusting for age, sex and relevant co-variates. Instead, overweight people displayed the lowest risk and underweight individuals the highest risk for adjusted all-cause mortality
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02311231
Funding Statement
Research reported in this publication was funded by the Swedish federal government under the ALF agreement (ALFGBG-932636, ALFGBG-775351, ALFGBG-633141)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approved by the regional ethical committee in Gothenburg Nr 288-14
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
CLINICAL TRIAL REGISTRATION: NCT02311231
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos